Overview: MPS Type VI Quantitative TestIntroduction: The MPS Type VI Quantitative Test measures enzyme activity to diagnose Maroteaux-Lamy syndrome, causing skeletal issues or organ enlargement. Following 2023 NORD guidelines, it uses quantitative assay for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected MPS Type VI.
Other Names: MPS Type VI Assay, Arylsulfatase B Activity Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MPS Type VI testing began in the 1970s with lysosomal storage research. Quantitative assays improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures arylsulfatase B activity to diagnose Maroteaux-Lamy syndrome, guides treatment, and evaluates patients with skeletal issues or organ enlargement.
Test Parameters: 1. Arylsulfatase B Activity
Pretest Condition: No fasting required. Collect whole blood or fibroblasts. Report history of skeletal issues or organ enlargement.
Specimen: Whole Blood (EDTA, 2-5 mL), Fibroblasts (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document skeletal issues, organ enlargement, or family history of lysosomal storage diseases. Include current medications, especially enzyme replacement therapy.
Consent: Written consent required, detailing the tests purpose, Maroteaux-Lamy syndrome implications, and risks of sample collection.
Procedural Considerations: Uses quantitative assay to measure arylsulfatase B activity in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for MPS Type VI diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or low cell viability can affect results. Contamination may reduce specificity.
Clinical Significance: Reduced arylsulfatase B activity confirms Maroteaux-Lamy syndrome, guiding enzyme replacement therapy. Normal activity may require genetic testing.
Specialist Consultation: Consult a geneticist or metabolic specialist for result interpretation and treatment planning.
Additional Supporting Tests: ARSB gene sequencing, urine GAG testing, or skeletal imaging to confirm Maroteaux-Lamy syndrome diagnosis.
Test Limitations: Pseudodeficiency may mimic results; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD MPS Guidelines, 2023; Journal of Inherited Metabolic Disease, Muenzer J, 2022.
